ASIA PACIFIC BLOOD PLASMA MARKET FORECAST 2020-2028

  • You are here:
  • Home
  • Reports
  • ASIA PACIFIC BLOOD PLASMA MARKET FORECAST 2020-2028

ASIA PACIFIC BLOOD PLASMA MARKET FORECAST 2020-2028

The Asia Pacific blood plasma market is projected to register a CAGR of 6.59% during the forecast period, 2020-2028. The factors evaluated to impact the growth of the market are the increasing number of organizations that ensure the supply of blood plasma, along with the presence of countries that are major contributors in terms of market growth aspects of the region.

ASIA PACIFIC BLOOD PLASMA MARKET FORECAST 2020-2028

Asia Pacific Blood Plasma Market by Mode of Delivery (Infusion Solutions, Gels, Sprays, Biomedical Sealants) by Blood Type (Immunoglobulin, Albumin, Hyperimmunes, Coagulation Factor Concentrates, Other Plasma Fractionation Products) by Therapeutic Indication (Immunology, Oncology, Pulmonology, Rheumatology, Transplantation, Neurology, Hematology, Other Application) by Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, Von Willebrand Disease (Vwd), Other Application)  by End User (Hospitals and Clinics, Research Laboratories, Academic Institutions) and by Geography.

Request free sample

The Asia Pacific blood plasma market is projected to register a CAGR of 6.59% during the forecast period, 2020-2028. The factors evaluated to impact the growth of the market are the increasing number of organizations that ensure the supply of blood plasma, along with the presence of countries that are major contributors in terms of market growth aspects of the region.
Asia Pacific Blood Plasma Market

To know more about this report, request a free sample copy.

The countries analyzed in the Asia Pacific blood plasma market Australia & New Zealand, South Korea, Japan, Thailand, Vietnam, China, Indonesia, India, and the rest of Asia Pacific. In China, there is wide use of blood plasma for various therapeutic treatments, and the country is making huge contributions to the blood plasma market in the Asia Pacific region. China also accounted for a significant number of fractionation facilities, which is highest in the Asia Pacific region. The country encompasses lucrative opportunities in terms of novel plasma therapy production. The hospital industry of the country is recording rapid growth due to advanced healthcare reforms. According to an article, the country is one of the largest manufacturers or consumers in the plasma-derived product’s market. The population in China is at the risk of developing cirrhosis and liver cancer due to the high number of chronic hepatitis cases. A large number of patients with liver diseases are responsible for the high consumption of albumin.

China Biologic Products Inc is a company that integrates the manufacture of plasma-based products. The company has achieved expertise in the areas of R&D, commercialization of biopharmaceutical products, and plasma collection. The company offers varied products through its immunoglobulin segment. The extensive geographical presence is the major strength of the company, along with a strong financial position that allows further investments.

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • MARKET DEFINITION
    •    KEY DRIVERS
      • WIDESPREAD ACCEPTANCE OF IMMUNOGLOBULIN-BASED THERAPIES
      • GROWING USAGE OF ALBUMIN IN OTHER THERAPEUTIC AREAS
      • GROWING GERIATRIC POPULATION
      • RISING PREVALENCE OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
      • INCREASE IN THE PATIENT POOL FOR HEMOPHILIA TREATMENT
    •    KEY RESTRAINTS
      • INCREASING USAGE OF RECOMBINANT PLASMA PRODUCTS IN THERAPEUTIC TREATMENTS
      • HIGH COSTS OF BLOOD PLASMA TREATMENTS
      • ADVERSE REACTIONS ASSOCIATED WITH POST-TRANSFUSION
      • SPREAD OF PATHOGENIC CONTAMINANTS
      • HIGH REGULATIONS IN THE MARKET
  1. KEY ANALYTICS
    •    PORTER’S FIVE FORCES ANALYSIS
      • THREAT OF NEW ENTRY
      • THREAT OF SUBSTITUTION
      • BUYER’S POWER
      • SUPPLIER’S POWER
      • COMPETITIVE RIVALRY
    • PLASMA THERAPEUTICS REGULATION
    • CLINICAL GUIDELINES
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • KEY INVESTMENT INSIGHTS
  2. MARKET BY MODE OF DELIVERY
    • INFUSION SOLUTIONS
    • GELS
    • SPRAYS
    • BIOMEDICAL SEALANTS
  3. MARKET BY DISORDER
    • IMMUNODEFICIENCY DISEASE
    • HYPOGAMMAGLOBULINEMIA
    • HEMOPHILIA
    • VON WILLEBRAND DISEASE (VWD)
    • OTHER DISORDERS
  4. MARKET BY BLOOD PLASMA DERIVATIVES
    •    IMMUNOGLOBULIN
      • INTRAVENOUS IMMUNOGLOBULIN
      • SUBCUTANEOUS IMMUNOGLOBULIN
      • OTHER IMMUNOGLOBULIN TYPES
    • ALBUMIN
    • HYPERIMMUNE
    • COAGULATION FACTOR CONCENTRATES
    • OTHER PLASMA FRACTIONATION PRODUCTS
  5. MARKET BY THERAPEUTIC INDICATION
    • NEUROLOGY
    • IMMUNOLOGY
    • ONCOLOGY
    • TRANSPLANTATION
    • HEMATOLOGY
    • RHEUMATOLOGY
    • PULMONOLOGY
    • OTHER THERAPEUTIC INDICATION
  6. MARKET BY END-USER
    • HOSPITALS AND CLINICS
    • RESEARCH LABORATORIES
    • ACADEMIC INSTITUTIONS
  7. GEOGRAPHICAL ANALYSIS
    •    ASIA PACIFIC
      • JAPAN
      • CHINA
      • AUSTRALIA & NEW ZEALAND
      • INDIA
      • SOUTH KOREA
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
  1. COMPANY PROFILES
    • ADMA BIOLOGICS
    • ARTHREX
    • BIO PRODUCTS LABORATORY
    • BAXTER INTERNATIONAL
    • BIOTEST AG
    • CERUS CORPORATION (CERUS)
    • CHINA BIOLOGIC PRODUCTS
    • CSL LIMITED
    • FUSION HEALTH CARE
    • GREEN CROSS HOLDINGS CORPORATION
    • GRIFOLS
    • LFB
    • OCTAPHARMA
    • TAKEDA PHARMACEUTICAL COMPANY
    • KEDRION BIOPHARMA INC

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – BLOOD PLASMA

TABLE 2: ASIA PACIFIC BLOOD PLASMA MARKET, BY DISORDER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 3: ASIA PACIFIC BLOOD PLASMA MARKET, BY DISORDER, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 4: ASIA PACIFIC BLOOD PLASMA MARKET, BY BLOOD DERIVATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 5: ASIA PACIFIC BLOOD PLASMA MARKET, BY BLOOD DERIVATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 6: ASIA PACIFIC BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 7: ASIA PACIFIC BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 8: ASIA PACIFIC BLOOD PLASMA MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 9: ASIA PACIFIC BLOOD PLASMA MARKET, BY END-USER, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 10: ASIA PACIFIC BLOOD PLASMA, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 11: ASIA PACIFIC BLOOD PLASMA, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: IMMUNOGLOBULIN INFUSIONS SIDE EFFECTS

FIGURE 6: ROLE OF FIBRIN SEALANT IN COAGULATION CASCADE

FIGURE 7: ASIA PACIFIC BLOOD PLASMA MARKET, BY DISORDER, IN 2019

FIGURE 8: ASIA PACIFIC BLOOD PLASMA MARKET, BY IMMUNODEFICIENCY DISEASE, 2020-2028 (IN $ MILLION)

FIGURE 9: ASIA PACIFIC BLOOD PLASMA MARKET, BY HYPOGAMMAGLOBULINEMIA, 2020-2028 (IN $ MILLION)

FIGURE 10: ASIA PACIFIC BLOOD PLASMA MARKET, BY HEMOPHILIA, 2020-2028 (IN $ MILLION)

FIGURE 11: ASIA PACIFIC BLOOD PLASMA MARKET, BY VON WILLEBRAND DISEASE (VWD), 2020-2028 (IN $ MILLION)

FIGURE 12: ASIA PACIFIC BLOOD PLASMA MARKET, BY OTHER DISORDERS, 2020-2028 (IN $ MILLION)

FIGURE 13: ASIA PACIFIC BLOOD PLASMA MARKET, BY BLOOD DERIVATIVES, IN 2019

FIGURE 14: ASIA PACIFIC BLOOD PLASMA MARKET, BY IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)

FIGURE 15: ASIA PACIFIC IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)

FIGURE 16: ASIA PACIFIC IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)

FIGURE 17: ASIA PACIFIC IMMUNOGLOBULIN MARKET, BY OTHER IMMUNOGLOBULIN TYPES, 2020-2028 (IN $ MILLION)

FIGURE 18: ASIA PACIFIC BLOOD PLASMA MARKET, BY ALBUMIN, 2020-2028 (IN $ MILLION)

FIGURE 19: ASIA PACIFIC BLOOD PLASMA MARKET, BY HYPERIMMUNE, 2020-2028 (IN $ MILLION)

FIGURE 20: HYPERIMMUNES ISOLATION PROCESS

FIGURE 21: ASIA PACIFIC BLOOD PLASMA MARKET, BY COAGULATION FACTOR CONCENTRATES, 2020-2028 (IN $ MILLION)

FIGURE 22: ASIA PACIFIC BLOOD PLASMA MARKET, BY OTHER PLASMA FRACTIONATION PRODUCTS, 2020-2028 (IN $ MILLION)

FIGURE 23: ASIA PACIFIC BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, IN 2019

FIGURE 24: ASIA PACIFIC BLOOD PLASMA MARKET, BY NEUROLOGY, 2020-2028 (IN $ MILLION)

FIGURE 25: ASIA PACIFIC BLOOD PLASMA MARKET, BY IMMUNOLOGY, 2020-2028 (IN $ MILLION)

FIGURE 26: ASIA PACIFIC BLOOD PLASMA MARKET, BY ONCOLOGY, 2020-2028 (IN $ MILLION)

FIGURE 27: ASIA PACIFIC BLOOD PLASMA MARKET, BY TRANSPLANTATION, 2020-2028 (IN $ MILLION)

FIGURE 28: ASIA PACIFIC BLOOD PLASMA MARKET, BY HEMATOLOGY, 2020-2028 (IN $ MILLION)

FIGURE 29: ASIA PACIFIC BLOOD PLASMA MARKET, BY RHEUMATOLOGY, 2020-2028 (IN $ MILLION)

FIGURE 30: LUPUS INFECTION SYMPTOMS

FIGURE 31: ASIA PACIFIC BLOOD PLASMA MARKET, BY PULMONOLOGY, 2020-2028 (IN $ MILLION)

FIGURE 32: ASIA PACIFIC BLOOD PLASMA MARKET, BY OTHER THERAPEUTIC INDICATION, 2020-2028 (IN $ MILLION)

FIGURE 33: ASIA PACIFIC BLOOD PLASMA MARKET, BY END-USER, IN 2019

FIGURE 34: ASIA PACIFIC BLOOD PLASMA MARKET, BY HOSPITALS AND CLINICS, 2020-2028 (IN $ MILLION)

FIGURE 35: ASIA PACIFIC BLOOD PLASMA MARKET, BY RESEARCH LABORATORIES, 2020-2028 (IN $ MILLION)

FIGURE 36: ASIA PACIFIC BLOOD PLASMA MARKET, BY ACADEMIC INSTITUTIONS, 2020-2028 (IN $ MILLION)

FIGURE 37: ASIA PACIFIC BLOOD PLASMA MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 38: JAPAN BLOOD PLASMA, 2020-2028 (IN $ MILLION)

FIGURE 39: CHINA BLOOD PLASMA, 2020-2028 (IN $ MILLION)

FIGURE 40: AUSTRALIA & NEW ZEALAND BLOOD PLASMA, 2020-2028 (IN $ MILLION)

FIGURE 41: INDIA BLOOD PLASMA, 2020-2028 (IN $ MILLION)

FIGURE 42: SOUTH KOREA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 43: THAILAND BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 44: INDONESIA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 45: VIETNAM BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

FIGURE 46: REST OF ASIA PACIFIC BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)

  1. GEOGRAPHICAL ANALYSIS
    •    ASIA PACIFIC
      • JAPAN
      • CHINA
      • AUSTRALIA & NEW ZEALAND
      • INDIA
      • SOUTH KOREA
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
  1. MARKET BY MODE OF DELIVERY
    • INFUSION SOLUTIONS
    • GELS
    • SPRAYS
    • BIOMEDICAL SEALANTS
  2. MARKET BY DISORDER
    • IMMUNODEFICIENCY DISEASE
    • HYPOGAMMAGLOBULINEMIA
    • HEMOPHILIA
    • VON WILLEBRAND DISEASE (VWD)
    • OTHER DISORDERS
  3. MARKET BY BLOOD PLASMA DERIVATIVES
    •    IMMUNOGLOBULIN
      • INTRAVENOUS IMMUNOGLOBULIN
      • SUBCUTANEOUS IMMUNOGLOBULIN
      • OTHER IMMUNOGLOBULIN TYPES
    • ALBUMIN
    • HYPERIMMUNE
    • COAGULATION FACTOR CONCENTRATES
    • OTHER PLASMA FRACTIONATION PRODUCTS
  4. MARKET BY THERAPEUTIC INDICATION
    • NEUROLOGY
    • IMMUNOLOGY
    • ONCOLOGY
    • TRANSPLANTATION
    • HEMATOLOGY
    • RHEUMATOLOGY
    • PULMONOLOGY
    • OTHER THERAPEUTIC INDICATION
  5. MARKET BY END-USER
    • HOSPITALS AND CLINICS
    • RESEARCH LABORATORIES
    • ACADEMIC INSTITUTIONS

To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now